Martin Rohrbach – Partner & Head of Life Sciences, KPMG Switzerland
Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics touched upon by KPMG Switzerland’s head of life sciences Martin Rohrbach.
On February 12th the Swiss people rejected the Tax III reform via referendum. What does this mean for the Swiss business community?
Tax reform has become necessary in Switzerland as the OECD is pushing for the harmonization of international tax systems, but the Swiss people rejected the package of proposed reforms via referendum on February 12th. Now this means that Switzerland and the business community here will have to find other ways to respond to the OECD’s demand. The private sector will have to play a role here and lead the discussion on alternatives.